Related Experiment Videos
Specific inhibition of the classical complement pathway by C1q-binding peptides
1Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands. A.Roos@LUMC.NL
Journal of Immunology (Baltimore, Md. : 1950)
|December 12, 2001
Summary
A novel peptide, 2J, effectively inhibits the classical complement pathway by targeting C1q binding. This specific inhibition prevents complement-mediated damage in diseases like xenograft rejection without compromising essential antimicrobial functions.
Area of Science:
- Immunology
- Biochemistry
- Drug Discovery
Background:
- Complement system activation drives immune complex diseases and xenograft rejection.
- Targeting the classical complement pathway offers therapeutic potential without impairing innate immunity.
Purpose of the Study:
- To identify and characterize peptide inhibitors of the C1q-mediated classical complement pathway.
- To develop a therapeutic agent for preventing complement-mediated pathological conditions.
Main Methods:
- Synthesis and screening of 42 peptides for C1q inhibitory activity.
- Assessing peptide inhibition of C1q hemolytic activity and alternative pathway function.
- ELISA and cell-based assays to evaluate C1q binding, complement activation, and deposition.
Main Results:
- Peptide 2J demonstrated potent inhibition of C1q hemolytic activity across multiple species.
- 2J binds to the globular head of C1q, inhibiting C1q-IgG interaction and downstream classical pathway activation (C4, C3, C5b-9).
- 2J significantly reduced C4 and C3 deposition on xenogeneic cells.
Conclusions:
- Peptide 2J is a potent inhibitor of the classical complement pathway's initiation step.
- 2J shows promise as a therapeutic agent for complement-mediated diseases, including hyperacute xenograft rejection.